Close-up of a laboratory microscope beside glassware, with a molecular structure overlaid.

The biggest pieces of equipment usually have a destination when a pharmaceutical site closes. Waste management in life sciences is often about the items around them: surplus lab consumables, scientific glassware, office furniture and equipment that surface during closures, relocations, refurbishments and clearances, and deciding what can be reused or redistributed rather than discarded.

For facilities, procurement, sustainability and compliance teams in life sciences and pharmaceutical organisations, that decision shapes landfill diversion, carbon reporting, ESG evidence and social value as much as disposal cost. This article looks at ethical clearance planning, reuse pathways for lab and office assets, global charity and education partnerships, and the reporting that shows what was saved, donated and kept in circulation, including a case study from GSK’s decommissioning project.

When GSK began decommissioning a facility in Rockville, Maryland, its team found surplus glassware and lab consumables that hadn’t been accounted for in the original clearance plan. Recycling was an option. The team asked a question that changed the outcome: who could still use these materials?

The answer was universities and colleges training the next generation of scientists.

Make reuse part of the clearance plan to reduce environmental impact

Waste management in life sciences and pharmaceuticals starts with knowing what’s on site, separating reusable assets from pharmaceutical waste, which can include expired medications and contaminated packaging, and deciding where it can go. For facilities and procurement teams planning a relocation, refurbishment or closure, a site survey is a chance to ask three practical questions.

  • What can we use elsewhere? Another site may have a use for furniture, storage or equipment that’s surplus to the project.

  • What could we donate? Schools, charities and educational institutions may be able to use suitable assets. The condition of the items and what recipients actually need should guide the decision.

  • What needs another route? Involve the site’s safety and compliance teams early so they can confirm which assets can be released for reuse and which need specialist handling, as some materials require specialist pharmaceutical waste disposal to prevent environmental contamination.

Timing matters. Once a clearance date is set, finding recipients, arranging transport and coordinating deliveries all have to fit around it. An early inventory gives teams more time to make those arrangements and helps them spot opportunities that might otherwise be missed.

From Decommission to Discovery: Addressing improper disposal · The GSK USA case study

GSK’s site closure was already under way when the team identified the additional materials. The timetable was tight, and there was no established local route for reuse at this scale. GSK’s procurement team helped bring Waste to Wonder Worldwide on board, showing the manufacturer’s responsibility to support wider stakeholders and the role of collaboration with healthcare and education partners, and we matched the surplus scientific glassware and lab consumables with universities and colleges that could put them to work.

GSK project results

Impact

Materials retained for reuse

246,613 kg

Carbon savings through reuse

38,115 kg

Fair market value of donated materials

£223,306

For the institutions receiving the donations, the supplies helped stretch teaching budgets. Collaboration across healthcare professionals, manufacturers and institutions can reduce waste beyond a single-site project. For students, they meant more opportunities to get hands-on experience, build confidence with unfamiliar equipment and learn to work safely in a lab. The materials had reached the end of their use at one site and could now help more students build the skills to pursue a career in science.

An example is how regional hospitals can optimize orders to cut waste and carbon footprint.

Watch the GSK case study, From Decommission to Discovery

GSK USA staff standing holding boxes and a large number of cardboard boxes behind them. Thumail for video cover

A snapshot of our work across the pharmaceutical industry sector

Waste to Wonder Worldwide has worked with life sciences and pharmaceutical organisations including GSK, MSD, Pfizer, Sanofi, Vertex Pharmaceuticals and Boehringer Ingelheim. The figures below cover 53 projects delivered between 2024 and November 2026, a snapshot of our wider work in the sector.

Impact across 53 recent projects

Result

Items redistributed

11,099

Total weight collected

506,628 kg

Weight retained for reuse

505,108 kg

Reuse rate by weight

99.7%

Carbon savings through reuse

673,045 kg

Fair market value of donated assets

£826,987

Combined social value

£1,120,864

Those projects included everyday workplace assets such as desks, chairs and storage cabinets, alongside IT equipment, laboratory glassware and consumables. Each brought a different mix of reusable assets and other waste streams. The opportunity was the same: find out what people could use and give those assets a second life, helping reduce environmental impact, support ESG goals, improve operational efficiency and protect the planet. More than 600 pharmaceuticals have been found in the environment around the world, and when compounds enter soil and water sources they can cause damage to aquatic ecosystems.

Account for what happens after pharmaceutical waste disposal collection

A clearance report should document what was collected, where the assets went, and how waste was tracked and managed from collection through final treatment and disposal. Our ESG reporting also covers auditing and compliance records, recording what was redistributed, the weight kept in use, the carbon savings associated with reuse and the fair market value of donated assets in line with relevant guidelines and regulations. Regulatory bodies have established guidelines for pharmaceutical waste disposal, and facilities may need to comply with requirements such as the Hazardous Waste Regulations and Environmental Permitting Regulations. That gives facilities, procurement and sustainability teams a record they can use after the site has closed or the move is complete, while ensuring hazardous waste transportation is properly evidenced.

If you’re planning a laboratory relocation, pharmaceutical site closure or office refurbishment, bring reuse into the conversation while there’s still time to plan where the assets could go. Clear documentation and regular audits help reduce compliance risks and improve future waste-management decisions. Contact Waste to Wonder Worldwide to arrange a site survey.

Are you looking for an ethical clearance provider?

We are office clearance specialists for socially conscious businesses. If you have an upcoming clearance project in Europe that you would like to see benefit communities, please get in touch to see how we can manage it for you.